Biogen Q3 2024 Adj EPS $4.08 Beats $3.79 Estimate, Sales $2.47B Beat $2.43B Estimate
Portfolio Pulse from Benzinga Newsdesk
Biogen reported Q3 2024 earnings per share of $4.08, surpassing the analyst estimate of $3.79, despite a year-over-year decrease. Sales were $2.47 billion, also beating expectations but down from last year.
October 30, 2024 | 10:51 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biogen's Q3 2024 earnings per share of $4.08 exceeded expectations, though both EPS and sales decreased compared to last year. The positive earnings surprise may boost short-term stock prices.
Biogen's earnings per share exceeded analyst expectations by 7.65%, which is typically a positive signal for investors and can lead to a short-term increase in stock price. However, the year-over-year decline in both EPS and sales may temper long-term enthusiasm.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100